Contract manufacturing and development partner for biologics and biosimilars
Enzene operates a dual-site CDMO (Pune and New Jersey) specializing in continuous manufacturing for biologics. The tech stack is heavily weighted toward manufacturing instrumentation (HPLC, UPLC, gas chromatography, atomic absorption spectroscopy) and ERP/quality systems (SAP, Veeva, LIMS), reflecting a regulated biotech operation. Active hiring skews heavily toward manufacturing and quality roles at senior/manager level, while project focus on validation protocols, tech transfer, and aseptic filling suggests preparation for new commercial campaigns or regulatory submission cycles.
Enzene Biosciences is a contract development and manufacturing organization (CDMO) founded in 2008, headquartered in Pune with a secondary site in Hopewell, New Jersey. The company serves biosimilar developers and biologic innovators through integrated discovery, development, and commercial manufacturing services. Their EnzeneX platform centers on fully-connected continuous manufacturing technology validated for commercial biologics supply. The organization spans 501–1,000 employees and operates under GMP and cGMP compliance frameworks; current operational priorities include stability programs, aseptic filling validation, and global quality system harmonization.
Enzene's EnzeneX platform features fully-connected continuous manufacturing (FCCM) technology validated for commercial biologics. The company operates dual manufacturing sites in Pune, India, and Hopewell, New Jersey.
Active projects include technology transfer protocol writing, aseptic filling validation, stability and sample receipt programs, global harmonization of quality systems, and validation of manufacturing processes for new product introduction.
Other companies in the same industry, closest in size